----
Q2 FY2026 EarningsQ2 FY26 results missed consensus estimates across key profitability metrics despite maintaining zero revenue in line with expectations. GAAP net loss was $7.7M vs. the $5.5M expected, while GAAP EPS of -$0.45 missed the -$0.29 consensus. The miss was primarily driven by a $3.6M non-cash charge related to the change in fair value of financial instruments, overshadowing a 48% YoY reduction in total operating expenses. Management expects current cash to fund operations into H2 2027, supported by a recent $49M private placement.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: CalciMedica(CALC) the EBIT is -4.012 M (+39.4%), Beat estimate;the EPS is -2.25 (-12.5%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
Revenue
TBA--
0.00B--
----
EBITExceed expectations
-0.00B39.40%
-0.01B6.36%
+0.00B33.04%
EPSMiss expectations
-2.2512.50%
-1.4527.50%
-0.800040.00%
Upcoming earnings report - Q3 FY2026
Available dateNov 9, 2026
Estimate Revenue$0
Estimate EBIT-$4.5 M
Estimate EPS-$1.275
Revenue
ActualEstimateUnit: USD
Quarterly
EBIT
ActualEstimateUnit: USD
Quarterly
Net income
ActualEstimateUnit: USD
Quarterly
EPS
ActualEstimateUnit: USD
Quarterly
